Caption Health Names Joseph DeVivo to the Board of Directors

His appointment adds extensive leadership experience from medical device and telehealth industries to Caption Health’s board

Joseph DeVivo, President, of Hospitals and Health Systems at Teladoc Health, has been added to Caption Health board of directors.  Caption Health, is a leader in using AI to improve heart ultrasound diagnostics.

Under Joseph DeVivo’s direction, the Teladoc enterprise virtual care platform and hardware business addresses the comprehensive needs of hospitals, health systems, retail clinics, and physician groups globally, enabling complimentary usage of the platform with extant workflows.

“We are thrilled to welcome Joe to the board at a time when Caption Health is poised to reshape the market,” said Steve Cashman, Caption Health President, and CEO. “Caption Health is making rapid progress in helping enable access to high-quality and affordable cardiac ultrasounds in any care setting. His medtech and telehealth experience will support our vision of using ultrasound to drive earlier disease detection and develop a network of top cardiac providers.”

Mr. DeVivo brings extensive leadership experience from across the medical device industry. He was CEO of InTouch Health until its acquisition by Teladoc Health (NYSE: TDOC) in 2020. Prior to InTouch, he served as President, CEO, and Director at AngioDynamics (NASDAQ: ANGO), which develops innovative, minimally invasive medical devices used by healthcare providers for vascular access, surgery, peripheral vascular disease, and oncology. Other leadership roles include global President of Smith & Nephew Orthopaedics (NYSE: SNN), CEO of RITA Medical (NASDAQ; RITA), and Vice President and General Manager at U.S. Surgical, a division of Tyco Healthcare.

“Caption Health’s success in getting cardiac ultrasound into the hands of non-experts is truly impressive,” said Mr. DeVivo. “By democratizing access to cardiovascular disease detection and diagnosis, the company is reducing treatment delays and saving lives.”

Active in industry leadership as well as philanthropy, Mr. DeVivo is also a member of the board of Mauna Kea Technologies, Nuvo Group, and St. Jude Children’s Research Hospital. He serves as Chairman for the Center of Digital Health for AdvaMed, and as incoming Treasurer of the American Telemedicine Association. He holds a Bachelor of Arts degree in Business Administration from the Robins School of Business at the University of Richmond.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.